相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naive HIV-Infected Patients
Matthew L. Rizk et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization
Frauke Christ et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy
Ruxandra Calin et al.
ANTIVIRAL THERAPY (2012)
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naive and pretreated patients
F. Saladini et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Dolutegravir for the treatment of HIV
Christine Katlama et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naive HIV-Infected Patients: SPARTAN Study Results
Michael J. Kozal et al.
HIV CLINICAL TRIALS (2012)
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors
R. Bucciardini et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2012)
Sustained Efficacy and Safety of Raltegravir After 5 Years of Combination Antiretroviral Therapy as Initial Treatment of HIV-1 Infection: Final Results of a Randomized, Controlled, Phase II Study (Protocol 004)
Eduardo Gotuzzo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults
Mark R. Underwood et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Paul E. Sax et al.
LANCET (2012)
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
Edwin DeJesus et al.
LANCET (2012)
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
Jean-Michel Molina et al.
LANCET INFECTIOUS DISEASES (2012)
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Jan van Lunzen et al.
LANCET INFECTIOUS DISEASES (2012)
Tolerability of HIV integrase inhibitors
Frederick J. Lee et al.
CURRENT OPINION IN HIV AND AIDS (2012)
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
Sherene Min et al.
AIDS (2011)
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
Calvin Cohen et al.
AIDS (2011)
Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143
Mathieu Metifiot et al.
AIDS (2011)
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Masanori Kobayashi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes
Kendra E. Hightower et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients: 156-Week Results From STARTMRK
Juergen K. Rockstroh et al.
CLINICAL INFECTIOUS DISEASES (2011)
Diketo Acids Derivatives as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain
R. Di Santo
CURRENT MEDICINAL CHEMISTRY (2011)
Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors
Alexandra U. Scherrer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2011)
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients
Isabelle Malet et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial
Sebastien Gallien et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
Jose-Luis Blanco et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir
Filippo Canducci et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
LEDGF Dominant Interference Proteins Demonstrate Prenuclear Exposure of HIV-1 Integrase and Synergize with LEDGF Depletion To Destroy Viral Infectivity
Anne M. Meehan et al.
JOURNAL OF VIROLOGY (2011)
Inhibition of the Interaction between HIV-1 Integrase and its Cofactor LEDGF/p75: A Promising Approach in Anti-Retroviral Therapy
L. De Luca et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2011)
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
Joseph J. Eron et al.
LANCET INFECTIOUS DISEASES (2011)
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
Esteban Martinez et al.
AIDS (2010)
Integrase Inhibitors: A Novel Class of Antiretroviral Agents
Jason J. Schafer et al.
ANNALS OF PHARMACOTHERAPY (2010)
Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
Roy T. Steigbigel et al.
CLINICAL INFECTIOUS DISEASES (2010)
Novel integrase inhibitors for HIV
Nicole Prada et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures
Alexandra U. Scherrer et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
Jeffrey L. Lennox et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study
Jose M. Gatell et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical Trial
Andrew R. Zolopa et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
Joseph J. Eron et al.
LANCET (2010)
Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles
Olivia Goethals et al.
VIROLOGY (2010)
Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1-Infected Patients: A Randomized Open-Label Trial
Nathalie De Castro et al.
CLINICAL INFECTIOUS DISEASES (2009)
Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
HIV-1 IN Inhibitors: 2010 Update and Perspectives
Christophe Marchand et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Identifying and Characterizing a Functional HIV-1 Reverse Transcriptase-binding Site on Integrase
Thomas A. Wilkinson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
Marianne Harris et al.
AIDS (2008)
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants
Masanori Kobayashi et al.
ANTIVIRAL RESEARCH (2008)
Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors
Olivia Goethals et al.
JOURNAL OF VIROLOGY (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Broad Antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)
Kazuya Shimura et al.
JOURNAL OF VIROLOGY (2008)
Role of PSIP1/LEDGF/p75 in Lentiviral Infectivity and Integration Targeting
Heather M. Marshall et al.
PLOS ONE (2007)
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
John M. Murray et al.
AIDS (2007)
Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
Srinivasan Ramanathan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled study
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration
Ming-Chieh Shun et al.
GENES & DEVELOPMENT (2007)
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Beatriz Grinsztejn et al.
LANCET (2007)
Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription
Charles W. Dobard et al.
JOURNAL OF VIROLOGY (2007)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
Edwin DeJesus et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Novel HIV-1 integrase inhibitors derived from quinolone antibiotics
M Sato et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase
K Zhu et al.
JOURNAL OF VIROLOGY (2004)
分享论文
